Triphase begins Phase I trial of marizomib-bevacizumab combination to treat glioblastoma
The open-label, multicenter, dose-escalation Phase I trial is designed to evaluate an intravenous (IV) formulation of marizomib in combination with bevacizumab (Avastin) in these patients. Patient enrollment is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.